Patent ID: 7671079

Claim:
A method for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I wherein X is CR 6 R 7 , O or S; n is an integer of 1 or 2; R 1 is H, halogen, CN, CHO, OR 9 , or a C 1 -C 6 alkyl, aryl or heteroaryl group each optionally substituted; R 2 is an optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl group or an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having an N atom at the bridgehead and optionally containing 1, 2, or 3 additional heteroatoms selected form N, O, or S; R 3 is H, halogen, CN, OR 19 , OCO 2 R 10 , CO 2 R 11 , CONR 12 R 13 , SO x R 14 , NR 15 R 16 , COR 17 , or a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, aryl or heteroaryl group each optionally substituted; R 4 and R 5 are each independently H or a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted, or R 4 and R 5 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N, or S; R 6 and R 7 are each independently H or an optionally substituted C 1 -C 6 alkyl group; R 9 , R 10 , R 11 , R 14 , R 17 , R 18 and R 19 are each independently H or a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R 12 and R 13 are each independently H or an optionally substituted C 1 -C 6 alkyl group or R 12 and R 13 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR 18 , or SO m ; R 15 and R 16 are each independently H or an optionally substituted C 1 -C 4 alkyl group or R 12 and R 13 may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, NR 18 , or SO m ; and x and m are each independently 0 or an integer of 1 or 2; or a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein the central nervous system disorder related to or affected by the 5-HT6 receptor is selected from the group consisting of an anxiety disorder; a cognitive disorder; attention deficit disorder; obsessive compulsive disorder; withdrawal from drug, alcohol or nicotine addiction; schizophrenia; depression; Alzheimer's disease; stroke; head trauma; and neuropathic pain.